SHARES:ML proves that bio is still a buy

Back to that perennially intriguing stock market chestnut: ML Laboratories, and its future prospects. At a market capitalisation of pounds 370.5m, clearly great things are expected - given that sales are currently running at a little over pounds 5m a year. However, many now believe the last year has seen all the ingredients put in place for a successful future. Its kidney dialysis fluid, Icodial, has been signed to world leader Baxter, while it has sold European distribution rights for a dry powder asthma inhaler to Medeva. No doubt, there is still some risk, with future income still something of a mystery. That said, the shares, at 275p have fallen substantially in recent months, in line with the shake-up in the biotech sector. Given that ML is well ahead of the pack, in terms of getting its products to market, the shares look better value than for some time. A tentative buy.

The food sector has hardly been the place to have your money invested over the last year - as one wag pointed out, it's not so much a case of picking the winners, as avoiding the losers. Perkins Food at least shows some faith in its future prospects, with a 1-for-6 rights issue for pounds 15.5m, to buy the Dutch Disselkoen Group. The attraction to Perkins is that the business, one of the largest fresh food exporters from the Netherlands, gives it instant access to Germany, including a toehold in the country's supermarket chains. With European borders disappearing, the deal should shore up the group's competitive position, while it can also sell its own fresh produce into Disselkoen. Although the Dutch group's margins are, like most fresh-produce suppliers', razor thin, the deal should be earnings neutral in 1997. While the shares, at 81.5p, are making a gradual recovery from the setbacks of 1992, now seems the time for a more whole- hearted commitment. Buy.

More food. If Perkins has yet to fully regain the confidence of investors, that old warhorse Associated British Foods (417p), continues to keep pace with the market. While the business rarely dazzles, nor does it let down shareholders. Tomorrow, it posts its final figures for 1996. Operating profit should come in at around pounds 378m, a gain of 13 per cent, with sales of pounds 5.64bn, up 15 per cent. The shares remain a buy.

A company that is listed over there - on Nasdaq, to be precise - is obtaining a listing over here. Through a placing on the London Stock Exchange, Xenova Group, the UK-based biotech company that develops drugs from natural micro-organisms, hopes to raise pounds 25m. Its first product should be ready for market by 2000. The XR5000 anti-cancer drug should enter clinical trials early next year. Other products include XR9051, to overcome multidrug resistance in cancer chemotherapy, with up to a pounds 1.4bn market. It also has tie-ins to Genentech, Genzyme and Warner-Lambert. Listing details will be published later this month, but the company has some exciting products, and could be worth following.

Tough times at car dealer Evans Halshaw, which announced it was closing a fifth of its dealerships, and taking a pounds 19.8m restructuring charge. To add to its woes, the group said August and September had been difficult for trading, with a consequent impact on full-year results. Although the shares were off only 5.5p, to 248.5p, the prospects are mixed. While the intention is to improve the return on capital, clearly the business is lagging behind its competitors, who have stolen a lead on it in many areas. EH professes it wants to build up its presence "in the larger conurbations, like Birmingham, Leicester and Sheffield". But there, of course, is where the competition is fiercest - although volumes, for successful sites, are far higher. That said, the final impact on full-year results could even be neutral, given the benefit of margin enhancement from the restructuring. Nevertheless, there are better value shares elsewhere in the sector. Sell.

Suggested Topics
Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Talent Acquisition Consultant

£22500 - £27000 per annum + OTE £45K: SThree: Since our inception in 1986, STh...

Recruitment Genius: Experienced Financial Advisers and Paraplanners

Negotiable: Recruitment Genius: This extremely successful and well-established...

Guru Careers: FX Trader / Risk Manager

Competitive with monthly bonus: Guru Careers: We are seeking an experienced FX...

Guru Careers: Investment Writer / Stock Picker

Competitive (Freelance) : Guru Careers: An Investment Writer / Stock Picker is...

Day In a Page

How to stop an asteroid hitting Earth: Would people co-operate to face down a global peril?

How to stop an asteroid hitting Earth

Would people cooperate to face a global peril?
Just one day to find €1.6bn: Greece edges nearer euro exit

One day to find €1.6bn

Greece is edging inexorably towards an exit from the euro
New 'Iron Man' augmented reality technology could help surgeons and firefighters, say scientists

'Iron Man' augmented reality technology could become reality

Holographic projections would provide extra information on objects in a person's visual field in real time
Sugary drinks 'are killing 184,000 adults around the world every year'

Sugary drinks are killing 184,000 adults around the world every year

The drinks that should be eliminated from people's diets
Pride of Place: Historians map out untold LGBT histories of locations throughout UK

Historians map out untold LGBT histories

Public are being asked to help improve the map
Lionel, Patti, Burt and The Who rock Glasto

Lionel, Patti, Burt and The Who rock Glasto

This was the year of 24-carat Golden Oldies
Paris Fashion Week

Paris Fashion Week

Thom Browne's scarecrows offer a rare beacon in commercial offerings
A year of the caliphate:

Isis, a year of the caliphate

Who can defeat the so-called 'Islamic State' – and how?
Marks and Spencer: Can a new team of designers put the spark back into the high-street brand?

Marks and Spencer

Can a new team of designers put the spark back into the high-street brand?
'We haven't invaded France': Italy's Prime Minister 'reclaims' Europe's highest peak

'We haven't invaded France'

Italy's Prime Minister 'reclaims' Europe's highest peak
Isis in Kobani: Why we ignore the worst of the massacres

Why do we ignore the worst of the massacres?

The West’s determination not to offend its Sunni allies helps Isis and puts us all at risk, says Patrick Cockburn
7/7 bombings 10 years on: Four emergency workers who saved lives recall the shocking day that 52 people were killed

Remembering 7/7 ten years on

Four emergency workers recall their memories of that day – and reveal how it's affected them ever since
Humans: Are the scientists developing robots in danger of replicating the hit Channel 4 drama?

They’re here to help

We want robots to do our drudge work, and to look enough like us for comfort. But are the scientists developing artificial intelligence in danger of replicating the TV drama Humans?
Time to lay these myths about the Deep South to rest

Time to lay these myths about the Deep South to rest

'Heritage' is a loaded word in the Dixie, but the Charleston killings show how dangerous it is to cling to a deadly past, says Rupert Cornwell
What exactly does 'one' mean? Court of Appeal passes judgement on thorny mathematical issue

What exactly does 'one' mean?

Court of Appeal passes judgement on thorny mathematical issue